The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Daniel PollyeaDuring the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub spoke to Daniel Pollyea, University of Colorado School of Medicine, Aurora, US. We asked: How have venetoclax combinations changed the way we treat AML?
How have venetoclax combinations changed the way we treat AML?
He discusses results from the randomized phase III study comparing venetoclax + azacitidine vs azacitidine alone as frontline treatment for elderly or unfit patients with AML. The data highlighted a significant improvement in response rates in patients receiving venetoclax + azacitadine vs azacitidine alone. Daniel Pollyea classifies this regimen as the standard of care for patients with newly diagnosed AML who are ineligible for intensive chemotherapy.
Venetoclax based regimens are not limited to unfit patients, but are also being explored in other subsets of patients with AML, such as those with poor prognostic risk factors for intensive chemotherapy.